Correction: Serum levels of APRIL, BAFF, and IL-10 in systemic lupus erythematosus have limited utility as biomarkers for disease activity or flare prediction - Takeaways - MDSpire

Correction: Serum levels of APRIL, BAFF, and IL-10 in systemic lupus erythematosus have limited utility as biomarkers for disease activity or flare prediction

  • By

  • Gabriela Rybka

  • Radosław Dziedzic

  • Kazimierz Węglarczyk

  • Mamert Milewski

  • Andżelika Siwiec-Koźlik

  • Sylwia Dziedzina

  • Marek Sanak

  • Jacek Musiał

  • Maciej Siedlar

  • Mariusz Korkosz

  • Joanna Kosałka-Węgiel

  • March 28, 2026

  • 0 min

Share

  • 1

    The study reevaluates serum levels of APRIL, BAFF, and IL-10 in systemic lupus erythematosus (SLE) patients.

  • 2

    The corrected data indicates that 41.7% of lupus nephritis patients were diagnosed via renal biopsy.

  • 3

    Only two patients were receiving immunosuppressive therapies other than hydroxychloroquine at enrollment.

  • 4

    No significant differences in cytokine levels were found between SLE patients with and without prior cyclophosphamide treatment.

  • 5

    The findings suggest limited roles for APRIL, BAFF, and IL-10 as biomarkers for SLE disease activity and flare prediction.

Original Source(s)

Related Content